Life Science Company News

Results 281 - 300 out of 500 displayed.

By: GlobeNewswire - 30 Apr 2024

Related companies: SOPHiA GENETICS, Inc.

Entourage Health Reports Fiscal Year 2023 Financial Results and Posts $54 Million in Total Revenues

By: GlobeNewswire - 30 Apr 2024

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

By: GlobeNewswire - 30 Apr 2024

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

By: GlobeNewswire - 30 Apr 2024

Related companies: InflaRx N.V.

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

By: GlobeNewswire - 30 Apr 2024

Related companies: Tenax Therapeutics Inc.

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

By: GlobeNewswire - 30 Apr 2024

Related companies: Daré Bioscience, Inc.

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

By: GlobeNewswire - 30 Apr 2024

Related companies: XOMA Corporation

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

By: GlobeNewswire - 30 Apr 2024

Related companies: Invivyd, Inc.

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

By: GlobeNewswire - 30 Apr 2024

Related companies: BioRestorative Therapies, Inc.

Mobile-health Network Solutions Opens New Retail Pharmacy

By: GlobeNewswire - 30 Apr 2024

Related companies: Mobile-health Network Solutions (MNDR)

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

By: GlobeNewswire - 30 Apr 2024

Related companies: Orchestra BioMed, Inc.

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

By: GlobeNewswire - 30 Apr 2024

Related companies: Ultragenyx Pharmaceutical Inc.

Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024

By: GlobeNewswire - 30 Apr 2024

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

By: GlobeNewswire - 30 Apr 2024

Related companies: Biora Therapeutics, Inc.

In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

By: GlobeNewswire - 30 Apr 2024

Related companies: Matinas BioPharma Holdings Inc.

Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update

By: GlobeNewswire - 30 Apr 2024

Related companies: Alimera Sciences, Inc.

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

By: GlobeNewswire - 30 Apr 2024

Related companies: INmune Bio Inc.

Reflect Scientific Inc Secures $550,000 Sale with Major BioPharma Company

By: GlobeNewswire - 30 Apr 2024

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

By: GlobeNewswire - 30 Apr 2024

Related companies: Panbela Therapeutics, Inc.

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

By: GlobeNewswire - 30 Apr 2024

Related companies: Akero Therapeutics, Inc.

Results 281 - 300 out of 500 displayed.

« 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 »

Enhance your business development with Biotechgate

Try for free »